Lin Yung-Hsiang, Chairman of TCI, announced that the company has initiated its “TCI Biotech 2.0” global manufacturing transformation. The plan adopts an “asset-light, distributed” strategy, aiming to establish six asset-light production bases and ten international sites to build a highly resilient and flexible global supply chain, while continuing to advance internationalization and product upgrades.

Although TCI’s third-quarter revenue declined year-on-year, improvements in product mix and cost structure drove gross margin to 44.19% and operating margin to 17.45%, both reaching this year’s highs. Net profit after tax rose counter-cyclically by 68% year-on-year, with quarterly EPS hitting 2.5, the highest in nearly eight quarters; cumulative EPS for the first three quarters reached 5.89.

Analysts noted that TCI’s GLP-1 product line saw increased sales in the U.S. and European markets, with major orders coming from international clients, providing high stability. The Sugar-Lock blood sugar management product received U.S. approval to claim efficacy, and shipments of these two new products are ramping up, positively contributing to gross margin.

Lin stated that in response to tariffs and geopolitical challenges, TCI is shifting from centralized to distributed manufacturing through the Biotech 2.0 plan. By adopting an “asset-light, distributed” approach and establishing factories near key markets, the company can respond rapidly to demand. The India facility is already operational and taking orders, while the next site is planned for Barcelona, Spain, targeting opportunities at the region’s largest health supplement expo, with completion expected within 18 months.

Regarding production processes and capacity, TCI’s anaerobic liquid manufacturing technology effectively prolongs the activity of health supplement products. Current annual capacity is over 30 million packs, with 95 million packs of orders pending. Following the commissioning of a new production line in May, efforts are underway to increase yield, with an additional line planned in Taiwan by April next year. Future new capacity will gradually be shifted to overseas sites to diversify production risk and stay close to market demand.

Looking ahead, TCI’s core strategy is to launch one “star product” every three years. After continued expansion of GLP-1 Formul sales, the next star product will focus on blood sugar management, featuring proanthocyanidins from peanut testa to reduce postprandial blood sugar fluctuations. It is expected to launch in 2026, marking a new wave of growth for the company.

Resource: 採輕資產、分散式策略 大江啟動生醫2.0計畫